公开(公告)号：WO2007117465A2

公开(公告)日：2007-10-18

申请号：PCT/US2007/008307

申请日：2007-04-02

Applicant: ABBOTT LABORATORIES ,  ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

Inventor： ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

IPC: A61K31/5377

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D409/14

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。

公开(公告)号：WO2011068899A1

公开(公告)日：2011-06-09

申请号：PCT/US2010/058598

申请日：2010-12-01

Applicant: ABBOTT LABORATORIES ,  WISHART, Neil ,  ARGIRIADI, Maria A. ,  BREINLINGER, Eric C. ,  CALDERWOOD, David J. ,  ERICSSON, Anna M. ,  FIAMENGO, Bryan A. ,  FRANK, Kristine E. ,  FRIEDMAN, Michael ,  GEORGE, Dawn M. ,  GOEDKEN, Eric R. ,  JOSEPHSOHN, Nathan S. ,  LI, Biqin C. ,  MORYTKO, Michael J. ,  MULLEN, Kelly D. ,  SOMAL, Gagandeep ,  STEWART, Kent D. ,  VOSS, Jeffrey W. ,  WALLACE, Grier A. ,  WANG, Lu ,  WOLLER, Kevin R.

Inventor： WISHART, Neil ,  ARGIRIADI, Maria A. ,  BREINLINGER, Eric C. ,  CALDERWOOD, David J. ,  ERICSSON, Anna M. ,  FIAMENGO, Bryan A. ,  FRANK, Kristine E. ,  FRIEDMAN, Michael ,  GEORGE, Dawn M. ,  GOEDKEN, Eric R. ,  JOSEPHSOHN, Nathan S. ,  LI, Biqin C. ,  MORYTKO, Michael J. ,  MULLEN, Kelly D. ,  SOMAL, Gagandeep ,  STEWART, Kent D. ,  VOSS, Jeffrey W. ,  WALLACE, Grier A. ,  WANG, Lu ,  WOLLER, Kevin R.

IPC: A01N43/42 ,  A61K31/44

CPC classification number: C07F9/06 ,  C07D471/14 ,  C07D487/14 ,  C07D498/14 ,  C07D513/14

Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供了式（Ia），（Ib），（Ic），（Id），（Ie），（If），（Ig），（Ih），（Ii），（Ij），（Ik） ，或（II），其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：WO2009099545A1

公开(公告)日：2009-08-13

申请号：PCT/US2009/000568

申请日：2009-01-29

Applicant: ABBOTT LABORATORIES ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  XIANG, Tao ,  WU, Chengbin ,  GHAYUR, Tariq

Inventor： ARGIRIADI, Maria A. ,  BORHANI, David W. ,  XIANG, Tao ,  WU, Chengbin ,  GHAYUR, Tariq

IPC: A61K39/395

CPC classification number: C30B29/58 ,  C07K1/306 ,  C07K16/244 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C30B7/00

Abstract: The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes.

Abstract translation: 本发明提供结晶抗体及其片段以及由此制备的晶体的方法。 更具体地，本发明提供了将人抗体和非人Fab片段单独或与其靶配体共晶结晶的方法。 例如，提供了包含结合IL-18的抗体125-2H的鼠Fab片段或抗体ABT-325的人Fab片段的结晶以及结合于鼠Fab片段的共晶体 到IL-18。 ABT-325和125-2H在组合位点特征和结构上有显着差异，从而说明了它们在不同表位同时结合IL-18的能力。

公开(公告)号：EP2247310A1

公开(公告)日：2010-11-10

申请号：EP09708386.9

申请日：2009-01-29

Applicant: Abbott Laboratories

Inventor： ARGIRIADI, Maria A. ,  BORHANI, David W. ,  XIANG, Tao ,  WU, Chengbin ,  GHAYUR, Tariq

IPC: A61K39/395

CPC classification number: C30B29/58 ,  C07K1/306 ,  C07K16/244 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C30B7/00

Abstract: The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes.

公开(公告)号：EP2001480A2

公开(公告)日：2008-12-17

申请号：EP07754773.5

申请日：2007-04-02

Applicant: ABBOTT LABORATORIES

Inventor： ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

IPC: A61K31/5377

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D409/14

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Abstract translation: 式（I）的新化合物或其式（I）的药用盐，前药和生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。